

RECEIVED  
CENTRAL FAX CENTER

APR 26 2005

SCHERING-PLOUGH CORPORATION  
LAW DEPARTMENT  
2000 GALLOPING HILL ROAD  
K-6-1, MAIL STOP 1990  
KENILWORTH, NEW JERSEY 07033  
(908) 298-4000

## FACSIMILE TRANSMITTAL SHEET

TO:	FAX NUMBER:
United States Patent Office	(703) 872-9306
FROM:	PHONE NUMBER:
Henry C. Jeanette	(908) 298-5041
TOTAL NO. OF PAGES INCLUDING COVER	DATE
4	April 26, 2005


**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call LaKeisha Robinson at (908) 298-5053.

## NOTES/COMMENTS:

Re: Application No. 10/680,393  
In Re Application of Arthur G. Taveras, et al., Filed: 10/07/2003  
Group Art Unit: 1626; Attorney Docket No. OC01643K1  
For: THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES  
AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS

Transmitted herewith are:

- Fax Cover Sheet (1 pg.)
- Certificate of Fax Transmission (1 pg.)
- Response (2 pgs.)

  
HENRY C. JEANETTE  
Attorney for Applicant  
Registration No. 30,856

PHONE: (908) 298-5041

FAX: (908) 298-5388

Attorney Docket No.: OC01643K1

Application No.: 10/680,393

Filing Date: 10/07/2003

First Named Inventor: Arthur G. Taveras et al.

PTO/SB/97 (08-03)  
Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. (703) 872-9306)

on April 26, 2005

Date

  
SignatureHenry C. Jeanette, Reg. No. 30,856

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document(s) being transmitted:

Fax Cover Sheet (1 pg.)

Certificate of Fax Transmission (1 pg.)

Response (2 pgs.)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

APR 26 2005

PATENT CASE NO. OC01643K1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X  
In re Application of: :  
  
ARTHUR G. TAVERS, et al. : Examiner: Taofiq A. Solola  
  
For Patent For: : Group Art Unit: 1626  
THIADIAZOLEDIOXIDES AND :  
THIADIAZOLEOXIDES AS CXC- AND CC- : Date: 04/26/2005  
CHEMOKINE RECEPTOR LIGANDS :  
Serial No.: 10/680,393 :  
Filed: 10/07/2003 :  
-----X

Schering-Plough Corporation  
Kenilworth, New Jersey 07033-0530Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Mail Stop: Amendment**RESPONSE**

Sir:

This is in response to the Office Action mailed March 30, 2005.

In view of the following remarks, reconsideration and favorable action on the claims is respectfully requested.

**REMARKS**

In response to the Restriction Requirement, Applicants elect, with traverse, the claims in Group I—i.e., the compounds of formula IA.